Signal active
Bio
Dandan Dong, Ph.D., is a Managing Director of Vivo Capital with a background in academic biomedical science research and translational medicine. Dr. Dong is the founding team member of VISEN Pharmaceuticals and currently serves as VISEN’s Chief Business Officer. She has more than nine years’ experience in healthcare investments in both the United States and China. She has been involved in multiple transactions in both countries and cross-border deals. She is a managing member of Vivo PANDA Fund, Vivo’s early-stage investment vehicle.
She has conducted research in infectious disease and immunology and published her research in multiple peer-reviewed journals, including Infection and Immunity, the Journal of Infectious Disease etc. Dr. Dong holds a Ph.D. in biomedical science from Fudan University and she has completed the Pre-doctoral Fellowship program at New York University School of Medicine.
Location
Palo Alto, California, United States, North America
Social
Primary Organization
2021
11-50
Biotechnology, Life Science, Pharmaceutical
Jobs history
3
ArriVent Biopharma
Chief Business OfficerChief Business Officer
2021 - Current
Visen Pharmaceuticals
Founder & Board Member
2018 - Current
Citrine Medicine
Co-founder
Invalid date - Current
Board and Advisor Roles
0
N/A
Invest in regions
Profile Resume
DanDan Dong is the Chief Business OfficerChief Business Officer at ArriVent Biopharma, based in United States, North America. With a background in Biotechnology, DanDan Dong has a rich history of leadership and innovation. DanDan Dong studied BS Biotechnology @ Sichuan University. Explore their detailed professional journey, key connections, and contributions to the industry on our platform.
Recommendation from your interest
N/A
Investment portfolio
1
0
Personal investment
0
There is no personal investment available on this profile
Partner investment
3
Annouced Date | Organization Name | Funding Round | Investor Name | Money Raised |
---|---|---|---|---|
Nov 13, 2018 | Visen Pharmaceuticals | Series A - Visen Pharmaceuticals | Vivo Capital | 40.0M |
Jan 07, 2021 | Kira Pharmaceuticals | Series B - Kira Pharmaceuticals | Vivo Capital | 53.5M |
Jan 08, 2021 | Visen Pharmaceuticals | Series B - Visen Pharmaceuticals | Vivo Capital | 150.0M |
Exits
0
There is no exit available on this Profile
Invest in industries
Recent Activity
There is no recent news or activity for this profile.